Takeda Partners with MiTest Health to Launch Innovative Disease Risk Prediction Tool to Redefine Crohn’s Disease Management

Read Full Article At The Original Source

LEXINGTON, Mass., Dec. 13, 2019 /PRNewswire/ — Takeda Pharmaceuticals U.S.A. (TSE: 4502) (NYSE:TAK) (“Takeda”) and MiTest Health LLC (“MiTest”), a pioneering health technology company, today announced an exclusive partnership to optimize MiTest’s personalized risk and outcome prediction…

Share:

Author: HEDGE

Hedge Accordingly was founded ahead of the global financial crisis in January of 2008, with the goal of providing our readers our unique take on The Latest News on Wall Street, Stocks, #Politics and Business news. Hedge Accordingly produces both original, and aggregated #Wallst news content from top publishers around the world. We curate aggregated content covering the latest news on politics, stocks, wall street, and the tech industry. We also provide free stock charting, quotes and a bitcoin, forex and currency exchange. Learn More About HEDGEaccordingly.com